Journal
VACCINE
Volume 33, Issue 52, Pages 7433-7443Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2015.09.093
Keywords
Malaria; Recombinant protein; Vaccine; Adjuvant; Plasmodium falciparum; Antibody
Categories
Funding
- UK Medical Research Council (MRC) [G1000527]
- U.S. Military Infectious Diseases Research Program (MIDRP)
- U.S. Agency for International Development (USAID) through an Interagency Agreement (IAA)
- Ministry of Education, Culture, Sports, Science and Technology of Japan [24249024]
- Global Health Innovative Technology Fund [GHIT RFP 2013-001]
- Intramural Research Program of the Division of Intramtral Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
- USAID
- EU FP7 Seventh Framework Program Theme [Health-2009-2.3.2-5, 242079]
- Danish Council for Strategic research [13127]
- European and Developing Countries Clinical Trials Partnership (EDCTP) [IP.2007.3110.001]
- MRC [G1000527, MR/K025554/1] Funding Source: UKRI
- Medical Research Council [MR/K025554/1, G1000527] Funding Source: researchfish
- Wellcome Trust [106917/Z/15/Z] Funding Source: researchfish
Ask authors/readers for more resources
Plasmodium parasites are the causative agent of human malaria, and the development of a highly effective vaccine against infection, disease and transmission remains a key priority. It is widely established that multiple stages of the parasite's complex lifecycle within the human host and mosquito vector are susceptible to vaccine-induced antibodies. The mainstay approach to antibody induction by subunit vaccination has been the delivery of protein antigen formulated in adjuvant. Extensive efforts have been made in this endeavor with respect to malaria vaccine development, especially with regard to target antigen discovery, protein expression platforms, adjuvant testing, and development of soluble and virus-like particle (VLP) delivery platforms. The breadth of approaches to protein-based vaccines is continuing to expand as innovative new concepts in next-generation subunit design are explored, with the prospects for the development of a highly effective multi-component/multi-stage/multi-antigen formulation seeming ever more likely. This review will focus on recent progress in protein vaccine design, development and/or clinical testing for a number of leading malaria antigens from the sporozoite-, merozoite- and sexual-stages of the parasite's lifecycle-including PfCeITOS, PfMSP1, PfAMA1, PfRH5, PfSERA5, PfGLURP, PfMSP3, Pfs48/45 and Pfs25. Future prospects and challenges for the development, production, human delivery and assessment of protein-based malaria vaccines are discussed. (C) 2015 The Authors. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available